President’s Message

Dear Friends and Colleagues,

We are honored to have had three publications linked to Gynuity’s research named in 2023 as most-cited or most-read articles—two in the scientific journal Contraception and one in Gates Open Research.

The common thread uniting these three articles is the remote provision of medication abortion and along with our ongoing work they highlight our commitment to expanding the evidence base in support of self-care approaches that value an individual's dignity, autonomy and rights as well as other person-centered measures such as cost and convenience—guiding principles of central importance today as they were two decades ago when we first opened our doors.

Provision of medication abortion via telemedicine was identified by a respected source as a top breakthrough technology set to have a real impact on the world in years to come. We recognized the potential of this approach early and are incredibly proud to have been at the forefront of efforts to evaluate and demonstrate its feasibility. You can read more about our latest work in this area, including a new study in Ecuador to assess provision of misoprostol-only via telemedicine, in the Program Highlights section of this report.

This year, we conducted promising research into existing registered compounds that might be used in medication abortion regimens instead of mifepristone with similar safety and efficacy. We also published papers on a new protocol, an updated systematic review, and an analysis of patient data from a U.S. provider organization in relation to misoprostol alone for medication abortion.

The priorities of patients remained a focus of our maternal health research. With our partners, we published a paper reporting on a new way to capture patient experience and satisfaction during childbirth, the first in a collection of planned publications from our latest joint project in India evaluating the use of oral misoprostol for labor induction in pregnancies complicated by hypertension.

We extend our deep gratitude to all who guided, supported, and partnered with us over the course of 2023. The potential to do more is clear, and we are working hard to build on our accomplishments and learnings, including preparing for a randomized trial to assess regimens for treatment of early missed menses with partner clinics in Mexico.

Finally, a Gynuity strategy refresh is underway. We appointed an external consultant to steer the process and help us consider future areas of importance. Regardless of what we determine at the end of this process, we intend to continue taking risks, pushing boundaries, and exploring unproven ideas that help advance choice, scientific understanding, and safe innovation.

Thank you for your interest in what we do.

Beverly Winikoff
President